# Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06454890/  
OnCo record `nct06454890` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.

## Summary

The registry lists NCT06454890 as not yet recruiting, last updated 2024-06-12. Enrolment is 50 planned participants, an estimate. Interventions: Anti-Trop2 CAR-NK cell. Primary measures include Safety by Common Terminology Criteria for Adverse Events (CTCAE) V5.0; Objective Response Rate (ORR). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-10-06
- Registry id: NCT06454890
- Phase: 1/2
- Setting: An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Henan Cancer Hospital

## Sources

- ClinicalTrials.gov NCT06454890: https://clinicaltrials.gov/study/NCT06454890

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/nct06454890.json